Shares of Constellation Pharmaceuticals Inc (NASDAQ:CNST) saw unusually-strong trading volume on Friday . Approximately 1,273,709 shares traded hands during trading, an increase of 1,387% from the previous session’s volume of 85,647 shares.The stock last traded at $10.00 and had previously closed at $9.89.
A number of analysts have commented on CNST shares. Zacks Investment Research upgraded shares of Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research note on Wednesday, January 9th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Constellation Pharmaceuticals in a research note on Friday, January 4th. ValuEngine lowered shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Robert W. Baird started coverage on shares of Constellation Pharmaceuticals in a research note on Monday, January 28th. They set an “outperform” rating and a $17.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $17.25.
Constellation Pharmaceuticals (NASDAQ:CNST) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.03). On average, equities analysts predict that Constellation Pharmaceuticals Inc will post -4.14 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in shares of Constellation Pharmaceuticals by 16.9% in the 4th quarter. Geode Capital Management LLC now owns 13,735 shares of the company’s stock worth $55,000 after acquiring an additional 1,987 shares in the last quarter. Northern Trust Corp grew its stake in shares of Constellation Pharmaceuticals by 12.4% in the 4th quarter. Northern Trust Corp now owns 51,008 shares of the company’s stock worth $204,000 after acquiring an additional 5,624 shares in the last quarter. Dean Capital Investments Management LLC bought a new stake in shares of Constellation Pharmaceuticals in the 3rd quarter worth $351,000. VHCP Management III LLC bought a new stake in shares of Constellation Pharmaceuticals in the 3rd quarter worth $449,000. Finally, Sphera Funds Management LTD. bought a new stake in shares of Constellation Pharmaceuticals in the 4th quarter worth $281,000. Hedge funds and other institutional investors own 60.05% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Constellation Pharmaceuticals (CNST) Sees Large Volume Increase” was originally posted by Modern Readers and is the property of of Modern Readers. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.modernreaders.com/news/2019/03/17/constellation-pharmaceuticals-cnst-sees-large-volume-increase.html.
Constellation Pharmaceuticals Company Profile (NASDAQ:CNST)
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.
Further Reading: What causes a recession?
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.